MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

MDT

86.26

-0.28%↓

114.89

-0.48%↓

VEEV

174.73

+0.5%↑

HQY

83.39

-1.43%↓

PHR.US

9.05

+8.51%↑

Inicio・Lista de Acciones・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Cerrado

SectorSanidad

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

Máximo

Recomendaciones
By TipRanks
Recomendaciones	Neutral
Estimación a 12 Meses	-0.05% downside

Noticias sobre sentimiento de mercado

By Acuity

50%

141 / 349 Clasificación en Healthcare

Mirati Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 abr 2026, 23:17 UTC

Ganancias

Samsung Forecasts Record First-Quarter Operating Profit

6 abr 2026, 23:00 UTC

Acciones populares

Stocks to Watch: Health Insurers, Mawson, Owlet

6 abr 2026, 22:13 UTC

Principales Movimientos del Mercado

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 abr 2026, 21:46 UTC

Adquisiciones, fusiones, absorciones

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 abr 2026, 17:09 UTC

Principales Movimientos del Mercado

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 abr 2026, 16:56 UTC

Noticias de Eventos Importantes

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 abr 2026, 14:47 UTC

Principales Movimientos del Mercado

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 abr 2026, 00:00 UTC

Noticias de Eventos Importantes

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 abr 2026, 23:58 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 abr 2026, 23:50 UTC

Charlas de Mercado

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 abr 2026, 23:36 UTC

Charlas de Mercado

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 abr 2026, 23:15 UTC

Charlas de Mercado

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 abr 2026, 22:52 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

6 abr 2026, 22:52 UTC

Charlas de Mercado

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 abr 2026, 22:14 UTC

Charlas de Mercado

Correction to Live Cattle Futures Article

6 abr 2026, 20:56 UTC

Charlas de Mercado

Mexican Private Consumption Fell in January -- Market Talk

6 abr 2026, 20:50 UTC

Charlas de Mercado

Energy & Utilities Roundup: Market Talk

6 abr 2026, 20:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 abr 2026, 19:58 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 abr 2026, 19:58 UTC

Charlas de Mercado

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 abr 2026, 19:11 UTC

Charlas de Mercado

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 abr 2026, 19:06 UTC

Charlas de Mercado

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 abr 2026, 19:03 UTC

Charlas de Mercado

Global Energy Roundup: Market Talk

6 abr 2026, 19:03 UTC

Charlas de Mercado

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 abr 2026, 18:36 UTC

Adquisiciones, fusiones, absorciones

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 abr 2026, 17:59 UTC

Charlas de Mercado

Noticias de Eventos Importantes

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 abr 2026, 17:13 UTC

Adquisiciones, fusiones, absorciones

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 abr 2026, 16:33 UTC

Charlas de Mercado

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 abr 2026, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 abr 2026, 14:59 UTC

Ganancias

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Comparación entre iguales

Cambio de precio

Mirati Therapeutics Inc previsión

Precio Objetivo

By TipRanks

-0.05% descenso

Estimación a 12 Meses

Media 58.67 USD -0.05%

Máximo 59 USD

Mínimo 58 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Mirati Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Neutral

5 ratings

Comprar

Mantener

Vender

De acuerdo con 5 analistas que ofrecen calificaciones bursátiles a para Mirati Therapeutics Inc Dist en los últimos 3 meses.

Sentimiento

By Acuity

141 / 349 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

EBITDA

Beneficio operativo

Acerca de Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.